Lateral Flow Antibodies

Lateral flow tests are rapid immunochromatographic tests in strip format. They enable the detection of diverse analytes within just a few minutes. In addition to rapid results and ease of use, the advantages of lateral flow tests are low cost and high validity. Since they can be performed without complex infrastructure, they have versatile applications as point-of-care tests (POCT). antibodies-online offers a wide range of high quality antibodies suitable for utilization in lateral flow assays.

What is a Lateral Flow Test?

Lateral Flow Assays provide a simple and fast way to test a liquid patient sample, such as blood, urine, serum, saliva, sweat or other fluids, for a specific analyte. The first lateral flow test that entered the market was the Clearblue 1-step test in 1988 as a home test for the detection of the pregnancy hormone. In the past years, the technology has been utilized to great success in detection of infectious diseases, especially SARS-CoV-2.

How does a Lateral Flow Immunoassay Work?

Lateral flow tests are another variation of the ELISA in which antigens are immobilized on a strip of cellulose or other suitable matrix. As with other immunological assays, the test method is based on an antigen-antibody reaction.The sample is applied at one end of the strip and any antibodies present diffuse along it until they reach the position where the appropriate antigen is immobilized. Antibodies specific for the antigen bind to and remain at the site of the antigen and are visualized using labeled detection antibody.

Usually, a positive control antigen is placed on the strip so that it is encountered after the test antigen to confirm that the sample has diffused a sufficient distance to interact with the test antigen. More than one test antigen can be dotted on the strip to provide a multiplex test. Lateral flow tests can be used both qualitatively and quantitatively. This is done by interpreting the band intensity of the analyte using an optical reader.

Application Fields for Lateral Flow Assays

Lateral flow tests are widely across many industries sectors for point of care testing, including pharma, environmental testing, animal health, food and feed testing, and plant and crop health. As they can be performed by professionals, trained users or even patients, regardless of the equipment, lateral flow immunoassays are of particular value in medical diagnostic. Lateral flow tests are the most used type of rapid diagnostic test, a medical diagnostic test that is quick and easy to perform and used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals.

Important Targets in Laterflow Assays Development

Lateral Flow Assay Development

One of the key components to developing successful lateral flow assays is a sensitive and stable conjugate, which acts as a reporter particle. Covalent conjugation of antibodies to gold nanoparticles continues to become more widely used in commercial assays. With this method, less antibody is needed to maximize sensitivity, reducing the overall cost of an assay. The easy and consistent preparation saves time when performing antibody screening experiments. Additionally, the antibody-to-particle ratio can be precisely controlled.

Conjugation of Antibody to Gold Nanoparticles for Lateral Flow Assays

antibodies-online is able to support your lateral flow assay development. Try our high-performance gold conjugates which are ready to use in a lateral-flow assay. The Gold-in-a-Box™ Conjugation Kit enables optimal binding of an antibody/protein to our Naked Gold 20 nm and 40 nm highly concentrated gold sols, while retaining a high degree of specific activity through adjusting the pH of the gold sols to slightly above the isoelectric point of the coating antibody/protein.

Antibodies for Lateral Flow Assay Development

antibodies-online offers a wide range of high quality antibodies suitable for utilization in lateral flow assays. The focus of our portfolio lies on antibodies against compounds of the human body as well as various viruses. In addition, we also offer antibodies against fungi and bacteria. Discover our complete portfolio down below.
Especially for Lateral Flow Asssay development: Bulk price options available!

Selection of Lateral Flow Publications Citing antibodies-online

• Drugs of Abuse: Quantitative Point-of-Care Platform for the Assessment of Drugs of Abuse in Urine, Serum, and Whole Blood using ABIN723246 .¹
• Pregnancy: Development of a portable Raman/SERS-LFA reader using ABIN2143148 .²
• Influenza: Using ABIN573415 to develop a Dual Recognition Element Lateral Flow Assay Toward Multiplex Strain Specific Influenza Virus Detection. ³
• Bacterial Pathogens: Development of a Point-of-Care Magnetic Focus Lateral Flow Sensor for the Detection and profiling of pathogenic bacteria using ABIN6391433 .⁴
• SARS-CoV-2: Paper-Based Test for Rapid On-Site Screening of SARS-CoV-2 in Clinical Samples using ABIN6990129 .⁵
• Lyme Disease: Development of a multiplexed point-of-care immunodiagnostic assay for antibody detection in human sera made through the vertical stacking of functional paper layers using ABIN964717 .⁶

Antibodies against Borrelia burgdorferi for Lateral Flow Assays

Lyme disease is caused by spirochetal bacteria from the genus Borrelia. Borrelia burgdorferi is the predominant cause of Lyme disease in the United States, whereas Borrelia afzelii and Borrelia garinii are predominantly implicated in most European incidences. In addition to ABIN964717 we offer following antibodies against Borrelia burgdorferi targets:

References

All Lateral Flow Antibodies